Week in Review: BioSense Signs $68 Million China Deal with Neovacs For Therapeutic Vaccine

BioSense Global, a New Jersey-Suzhou biotech, signed a $68 million option agreement with France's Neovacs for China rights to a therapeutic vaccine aimed at lupus and dermatomyositis; Beijing's Anxin Doctor, a mobile health app focused on pediatric and women's healthcare, raised $28 million in a Series B round; Shanghai Fudan-Zhangjiang Bio-Pharma invested $2 million into Adgero Biopharma of New Jersey, a company developing photodynamic therapies; Ally Bridge Group made investments in two European biopharmas: Galenica AG of Switzerland, and Nabriva of Austria-US; Xynomic Pharma, a US-China oncology startup, acquired exclusive global rights to abexinostat, an HDAC inhibitor for cancer indications; Lee’s Pharm acquired Greater China rights to a treatment for oral mucositis from Japan's Solasia Pharma; Hutchison China MediTech (Chi-Med) and AstraZeneca started a China Phase II study of savolitinib, an oral c-Met inhibitor; and Qilu Pharma of Jinan launched its biosimilar version of AstraZeneca's Iressa in China. More details.... Stock Symbols: (Paris: ALNEV) (SIX: GALN) (NSDQ: NBRV) (HK: 0950) (AIM/Nasdaq: HCM) (NYSE: AZN) Share this with colleagues: // //